U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Pancreatic Ductal Adenocarcinoma

MedGen UID:
1733228
•Concept ID:
C5419537
•
Neoplastic Process

Definition

Pancreatic ductal adenocarcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Pancreatic Ductal Adenocarcinoma

Professional guidelines

PubMed

Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma.
Zhou H, Wang W, Cai Z, Jia ZY, Li YY, He W, Li C, Zhang BL
J Nanobiotechnology 2024 Jun 20;22(1):353. doi: 10.1186/s12951-024-02646-7. PMID: 38902759Free PMC Article
Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma.
Guo J, Wang Y, Chen J, Qiu W, Chen W
Int J Hyperthermia 2021;38(1):1375-1383. doi: 10.1080/02656736.2021.1962550. PMID: 34541997
Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.
Klaiber U, Schnaidt ES, Hinz U, Gaida MM, Heger U, Hank T, Strobel O, Neoptolemos JP, Mihaljevic AL, Büchler MW, Hackert T
Ann Surg 2021 Jan 1;273(1):154-162. doi: 10.1097/SLA.0000000000003270. PMID: 30921051

Recent clinical studies

Etiology

High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH, Ha HI, Jang JY, Lee JW, Choi JY, Bang S, Lee CH, Kim WB, Lee SS, Kim SC, Kang BK, Lee JM
Eur Radiol 2023 Sep;33(9):5965-5975. Epub 2023 Mar 29 doi: 10.1007/s00330-023-09584-2. PMID: 36988715
Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR
J Surg Oncol 2022 Mar;125(3):425-436. Epub 2021 Oct 31 doi: 10.1002/jso.26735. PMID: 34719035Free PMC Article
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
Zhou Y, Liao S, You J, Wu H
Updates Surg 2022 Feb;74(1):43-53. Epub 2021 May 21 doi: 10.1007/s13304-021-01089-1. PMID: 34021484
Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma.
Zhou Y, Gao S, Zhou B, Yuan S, Ren H, Wang Y, Guo X, Ren J, Chen Z, Hao J
Pancreatology 2021 Jun;21(4):763-770. Epub 2021 Feb 25 doi: 10.1016/j.pan.2021.02.016. PMID: 33712388
Biliary palliation for unresectable pancreatic adenocarcinoma: surgical bypass or self-expanding metal stent?
Stackhouse KA, Storino A, Watkins AA, Gooding W, Callery MP, Kent TS, Sawhney MS, Moser AJ
HPB (Oxford) 2020 Apr;22(4):563-569. Epub 2019 Sep 17 doi: 10.1016/j.hpb.2019.08.014. PMID: 31537457

Diagnosis

High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH, Ha HI, Jang JY, Lee JW, Choi JY, Bang S, Lee CH, Kim WB, Lee SS, Kim SC, Kang BK, Lee JM
Eur Radiol 2023 Sep;33(9):5965-5975. Epub 2023 Mar 29 doi: 10.1007/s00330-023-09584-2. PMID: 36988715
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Asama H, Ueno M, Kobayashi S, Fukushima T, Kawano K, Sano Y, Tanaka S, Nagashima S, Morimoto M, Ohira H, Maeda S
Pancreas 2022 Feb 1;51(2):148-152. doi: 10.1097/MPA.0000000000001985. PMID: 35404889
Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.
Zhang K, Dong S, Jing YH, Gao HF, Chen LY, Hua YQ, Chen H, Chen Z
BMC Cancer 2020 Jun 9;20(1):541. doi: 10.1186/s12885-020-07023-9. PMID: 32517802Free PMC Article
Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH, Cheng YJ, Jin ZY, Xue HD
Eur J Radiol 2019 Apr;113:188-197. Epub 2019 Feb 11 doi: 10.1016/j.ejrad.2019.02.009. PMID: 30927946
Second-look operation for unresectable pancreatic ductal adenocarcinoma at a high-volume center.
Michalski CW, Kleeff J, Bachmann J, Alkhatib J, Erkan M, Esposito I, Hinz U, Friess H, Büchler MW
Ann Surg Oncol 2008 Jan;15(1):186-92. Epub 2007 Oct 18 doi: 10.1245/s10434-007-9535-0. PMID: 17943388Free PMC Article

Therapy

Phase II study of SOXIRI (S-1/oxaliplatin/irinotecan) chemotherapy in patients with unresectable pancreatic ductal adenocarcinoma.
Wang F, Wang Y, Ren C, Li X, Qiu M, Li Y, Luo H, Peng R, Quan Q, Jiang Q, Li S, Guo G
Pancreatology 2024 Mar;24(2):241-248. Epub 2023 Dec 31 doi: 10.1016/j.pan.2023.12.008. PMID: 38195328
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Asama H, Ueno M, Kobayashi S, Fukushima T, Kawano K, Sano Y, Tanaka S, Nagashima S, Morimoto M, Ohira H, Maeda S
Pancreas 2022 Feb 1;51(2):148-152. doi: 10.1097/MPA.0000000000001985. PMID: 35404889
Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR
J Surg Oncol 2022 Mar;125(3):425-436. Epub 2021 Oct 31 doi: 10.1002/jso.26735. PMID: 34719035Free PMC Article
Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma.
Zhou Y, Gao S, Zhou B, Yuan S, Ren H, Wang Y, Guo X, Ren J, Chen Z, Hao J
Pancreatology 2021 Jun;21(4):763-770. Epub 2021 Feb 25 doi: 10.1016/j.pan.2021.02.016. PMID: 33712388
The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Kato A, Naiki-Ito A, Naitoh I, Hayashi K, Nakazawa T, Shimizu S, Nishi Y, Okumura F, Inoue T, Takada H, Kondo H, Yoshida M, Takahashi S, Joh T
Hum Pathol 2018 Apr;74:92-98. Epub 2018 Jan 12 doi: 10.1016/j.humpath.2018.01.009. PMID: 29339176

Prognosis

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P
Nat Cancer 2023 Sep;4(9):1362-1381. Epub 2023 Sep 7 doi: 10.1038/s43018-023-00628-6. PMID: 37679568Free PMC Article
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH, Ha HI, Jang JY, Lee JW, Choi JY, Bang S, Lee CH, Kim WB, Lee SS, Kim SC, Kang BK, Lee JM
Eur Radiol 2023 Sep;33(9):5965-5975. Epub 2023 Mar 29 doi: 10.1007/s00330-023-09584-2. PMID: 36988715
Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma.
McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O'Reilly EM, Varghese AM, Yu KH, Balachandran VP, Soares KC, D'Angelica MI, Drebin JA, Kingham TP, Allen PJ, Wei AC, Jarnagin WR
J Surg Oncol 2022 Mar;125(3):425-436. Epub 2021 Oct 31 doi: 10.1002/jso.26735. PMID: 34719035Free PMC Article
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma.
Buss EJ, Kachnic LA, Horowitz DP
Semin Oncol 2021 Feb;48(1):106-110. Epub 2021 Feb 23 doi: 10.1053/j.seminoncol.2021.02.005. PMID: 33771355
Biliary palliation for unresectable pancreatic adenocarcinoma: surgical bypass or self-expanding metal stent?
Stackhouse KA, Storino A, Watkins AA, Gooding W, Callery MP, Kent TS, Sawhney MS, Moser AJ
HPB (Oxford) 2020 Apr;22(4):563-569. Epub 2019 Sep 17 doi: 10.1016/j.hpb.2019.08.014. PMID: 31537457

Clinical prediction guides

Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P
Nat Cancer 2023 Sep;4(9):1362-1381. Epub 2023 Sep 7 doi: 10.1038/s43018-023-00628-6. PMID: 37679568Free PMC Article
High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH, Ha HI, Jang JY, Lee JW, Choi JY, Bang S, Lee CH, Kim WB, Lee SS, Kim SC, Kang BK, Lee JM
Eur Radiol 2023 Sep;33(9):5965-5975. Epub 2023 Mar 29 doi: 10.1007/s00330-023-09584-2. PMID: 36988715
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
Zhou Y, Liao S, You J, Wu H
Updates Surg 2022 Feb;74(1):43-53. Epub 2021 May 21 doi: 10.1007/s13304-021-01089-1. PMID: 34021484
Delta HU is a potential marker to predict chemotherapy response for unresectable pancreatic ductal adenocarcinoma.
Zhou Y, Gao S, Zhou B, Yuan S, Ren H, Wang Y, Guo X, Ren J, Chen Z, Hao J
Pancreatology 2021 Jun;21(4):763-770. Epub 2021 Feb 25 doi: 10.1016/j.pan.2021.02.016. PMID: 33712388
Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer.
Klaiber U, Schnaidt ES, Hinz U, Gaida MM, Heger U, Hank T, Strobel O, Neoptolemos JP, Mihaljevic AL, Büchler MW, Hackert T
Ann Surg 2021 Jan 1;273(1):154-162. doi: 10.1097/SLA.0000000000003270. PMID: 30921051

Recent systematic reviews

Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature.
Zhou Y, Liao S, You J, Wu H
Updates Surg 2022 Feb;74(1):43-53. Epub 2021 May 21 doi: 10.1007/s13304-021-01089-1. PMID: 34021484
Systematic review and trial sequential analysis of high-intensity focused ultrasound combined with chemotherapy versus chemotherapy in the treatment of unresectable pancreatic ductal adenocarcinoma.
Guo J, Wang Y, Chen J, Qiu W, Chen W
Int J Hyperthermia 2021;38(1):1375-1383. doi: 10.1080/02656736.2021.1962550. PMID: 34541997

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...